|
|
Intelence (Etravirine, TMC125)
| Brand Name: |
Intelence |
| Generic Name: |
Etravirine, TMC125 |
| Adult Single Dose: |
Two 100-mg tablets twice a day |
| Food & Liquid Restrictions: |
Take after a meal
|
| Drug Class: |
NNRTI |
|
| |
 |
| Click here for a summary of the essential details on Intelence (etravirine, TMC125) from Cal Cohen, M.D. |
|
The Basics
- An Overview of Intelence (TMC125, Etravirine) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
- Drug Watch: Next Generation NNRTIs: Etravirine and Rilpivirine (Winter 2008)
To read PDF, click here
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- News Analysis: U.S. Approval of Intelence (Etravirine) (January 25, 2008)
An interview with Cal Cohen, M.D., M.S.
From The Body
- Project Inform Welcomes Approval and Pricing of Intelence, Calls for Further Research (January 23, 2008)
From Project Inform
- Etravirine (Intelence) (January 20, 2008)
To read PDF, click here
From AIDS InfoNet
- Intelence (TMC125, Etravirine) Approved in United States (January 19, 2008)
From U.S. Food and Drug Administration
- Intelence (Etravirine, TMC-125) (January/February 2008)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- Intelence (TMC125, Etravirine) Patient Product Information (PDF) (January 2008)
From Tibotec Therapeutics
- Patient Information About Intelence (TMC125, Etravirine) (PDF) (January 2008)
From Tibotec Therapeutics
- Intelence (Etravirine) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
News & Research
- AAHIVM Encouraged by TMC125 Approval (January 22, 2008)
New HIV medication could offer more options for treatment-experienced patients.
From American Academy of HIV Medicine
- Fair Pricing Coalition Lauds Pricing of New Tibotec Drug (January 21, 2008)
From Fair Pricing Coalition
- FDA Receives New Drug Application for TMC125 (Etravirine) (July 20, 2007)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Adding Etravirine to Prezista Improves Anti-HIV Activity, Studies Show (July 6, 2007)
From aidsmap.com
- MK-0518 Plus Etravirine? No Problem! (January 5, 2007)
From Project Inform
- Tibotec Announces Expanded Access Programme for New NNRTI TMC125 (September 26, 2006)
From aidsmap.com
- Tibotec Pharmaceuticals Ltd. Announces Expanded Access Program for Its Investigational Agent TMC125 (September 25, 2006)
Program will provide early access for eligible HIV-1-infected patients who have limited treatment options.
From Tibotec Pharmaceuticals Ltd.
- AIDS Activists Urge Tibotec to Expand Access to TMC125, Show Compassion for HIV Salvage Patients (March 8, 2006)
From Salvage Therapies
- Behind the December 2004 "AIDS Breakthrough" Headlines (December 31, 2004)
Mid-December press reports were exaggerated, but still important; they focus on DAPYs, a promising new family of HIV meds.
In AIDS Treatment News, from AIDS Treatment News
- Research Updates on Tipranavir, TMC-114 and TMC-125 (December 2004)
A review of the tipranavir RESIST studies, a note on potential tipranavir pricing, and a critical look at two developing rescue drugs.
In TAGline, from Treatment Action Group
- Waiting in the Wings: More New Drugs (November/December 2003)
A look at 908, TMC-125 and entry inhibitors in development.
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- An Interview With Dr. Cal Cohen on Highlights From the 10th Conference on Retroviruses and Opportunistic Infections (April 4, 2003)
In AIDS Treatment News, from AIDS Treatment News
- TMC-125: A New NNRTI (March 2002)
To read PDF, click here
In Project Inform Perspective, from Project Inform
- TMC125 Monotherapy for 1 Week Results in a Similar Initial Rate of Decline of HIV-1 RNA as Therapy With a Five-Drug Regimen (February 25, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- TMC125 Is a Highly Potent Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) in Antiretroviral Therapy (ART)-Naive, HIV-1 Infected Subjects (December 17, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- One Week of Monotherapy with TMC-125, a Novel Highly Potent NNRTI, Produces a Mean 2-Log Reduction in Viral Load in Antiretroviral-Naive, HIV-1-Infected Volunteers (October 28, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
|
|
